SAN DIEGO – October 1, 2013 — OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the Cancer Vaccines and Gene Therapy Meeting at The Desmond Malvern Hotel in Philadelphia, Pennsylvania.
Dr. Richard Heller, Professor at Old Dominion University will be presenting pre-clinical data on the use of electroporation to deliver plasmid IL-12 in solid tumors in a presentation titled: Gene Electrotransfer as an Effective Delivery Tool. This presentation will take place on Thursday, October 3 at 3:30 PM ET.
Dr. Adil Daud, principal investigator and co-director of melanoma research at the University of California San Francisco School of Medicine will be presenting an update to OncoSec’s Phase II melanoma immune response data, which will include IL-12 expression findings in a presentation titled Gene Electrotransfer in Solid Tumors. This presentation will take place on Friday, October 4 at 1:00 PM ET.
About the Cancer Vaccines and Gene Therapy Meeting
The Cancer Vaccines and Gene Therapy Meeting will bring together important leaders to present and discuss the latest approaches and technologies used to develop promising anti-cancer therapeutics.